Keyphrases
Multidisciplinary Approach
100%
Patient Management
100%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
100%
Unmet Needs
100%
Androgen Receptor Antagonist
57%
Disease Progression
28%
Overall Survival
28%
Radiograph
28%
Metastasis-free Survival
28%
Clinical Trials
14%
Disease Management
14%
Disease Diagnosis
14%
Prostate Cancer
14%
Placebo
14%
Clinical Practice Guidelines
14%
Precision Medicine
14%
Enzalutamide
14%
Drug Interactions
14%
Patient Care
14%
Clinical Decision-making
14%
Rising Prostate-specific Antigen
14%
Prostate-specific Antigen Level
14%
Multidisciplinary Team
14%
Darolutamide
14%
Disease Monitoring
14%
Prostate-specific Antigen
14%
Consensus Recommendations
14%
Accuracy Improvement
14%
Disease Assessment
14%
Patient Well-being
14%
Treatment Landscape
14%
Radiotracer
14%
Patient Monitoring
14%
Quality of Survival
14%
Conventional Imaging
14%
Prostate-specific Antigen Kinetics
14%
Apalutamide
14%
Prostate-specific Membrane Antigen Positron Emission Tomography
14%
Drug Safety Profile
14%
Nursing and Health Professions
Castration Resistant Prostate Cancer
100%
Androgen Receptor
57%
Imaging
42%
Prostate Specific Antigen
42%
Disease Exacerbation
28%
Overall Survival
28%
Patient Monitoring
28%
Metastasis Free Survival
28%
Quality of Life
14%
Practice Guideline
14%
Disease Management
14%
Tracer
14%
Disease Detection
14%
Placebo
14%
Clinical Decision Making
14%
Prostate Cancer
14%
Disease Assessment
14%
Drug Safety
14%
Personalized Medicine
14%
Enzalutamide
14%
Prostate Specific Membrane Antigen
14%
Darolutamide
14%
Apalutamide
14%
Disease
14%
Patient Care
14%
Positron Emission Tomography
14%
Medicine and Dentistry
Castration Resistant Prostate Cancer
100%
Androgen Receptor
57%
Prostate Specific Antigen
42%
Disease
28%
Disease Exacerbation
28%
Overall Survival
28%
Metastasis Free Survival
28%
Patient Monitoring
28%
Prostate Cancer
14%
Clinical Trial
14%
Quality of Life
14%
Disease Management
14%
Personalized Medicine
14%
Patient Care
14%
Drug Interaction
14%
Positron Emission Tomography
14%
Clinical Decision Making
14%
Radioactive Tracer
14%
Conventional Imaging
14%
Drug Safety
14%
Prostate Specific Membrane Antigen
14%
Darolutamide
14%
Placebo
14%
Disease Assessment
14%
Apalutamide
14%
Enzalutamide
14%
Pharmacology, Toxicology and Pharmaceutical Science
Castration Resistant Prostate Cancer
100%
Androgen Receptor
57%
Disease
57%
Prostate Specific Antigen
42%
Disease Exacerbation
28%
Overall Survival
28%
Metastasis Free Survival
28%
Clinical Trial
14%
Enzalutamide
14%
Drug Safety
14%
Drug-Drug Interaction
14%
Placebo
14%
Prostate Cancer
14%
Darolutamide
14%
Prostate Specific Membrane Antigen
14%
Tracer
14%
Apalutamide
14%
Biochemistry, Genetics and Molecular Biology
Androgen Receptor
100%
Prostate-Specific Antigen
75%
Overall Survival
50%
Metastasis Free Survival
50%
Clinical Trial
25%
Drug Interaction
25%
Clinical Decision Making
25%
Drug Safety
25%
Positron Emission Tomography
25%
Enzalutamide
25%
Immunology and Microbiology
Prostate
100%
Prostate Specific Antigen
42%
Overall Survival
28%
Metastasis Free Survival
28%
Drug-Drug Interaction
14%
Prostate Specific Membrane Antigen
14%
Clinical Decision Making
14%
Drug Safety
14%
Positron Emission Tomography
14%